Intravesical chemotherapy is a treatment for bladder cancer in which a cancer-killing drug is delivered directly into the bladder through a catheter. Because the medication contacts the bladder lining without entering the bloodstream in significant amounts, it targets cancer cells locally while sparing the rest of the body from the harsh side effects of traditional chemotherapy. It is one of the most common treatments for non-muscle-invasive bladder cancer, the earliest stage of the disease.
How It Works
The word “intravesical” simply means “inside the bladder.” Instead of receiving chemotherapy through an IV that circulates throughout your entire body, the drug is placed right where the cancer is. A thin catheter is inserted through the urethra into the bladder, the bladder is drained, and the medication is instilled directly onto the bladder wall. This allows a high concentration of the drug to reach the tumor site with minimal absorption into the bloodstream, which is why patients generally don’t experience the systemic side effects people associate with chemotherapy, like hair loss, nausea, or immune suppression.
Who Is a Candidate
Intravesical chemotherapy is used for non-muscle-invasive bladder cancer (NMIBC), meaning the cancer is confined to the inner lining of the bladder and hasn’t grown into the deeper muscle wall. Current American Urological Association guidelines recommend it in two main scenarios.
The first is a single dose given within 24 hours after a tumor is surgically removed from the bladder (a procedure called TURBT). This post-operative instillation is recommended for patients with low- or intermediate-risk bladder cancer and has been shown to prolong the time before cancer comes back by roughly 38%. Put another way, for every nine patients who receive this single treatment, one recurrence is prevented.
The second scenario is a longer course of treatment. Intermediate-risk patients may receive a six-week induction course of intravesical chemotherapy, sometimes followed by ongoing maintenance treatments if they respond well. For high-risk patients who haven’t responded to immunotherapy with BCG (a different type of intravesical treatment that uses the immune system rather than chemotherapy drugs), combination chemotherapy regimens like gemcitabine with docetaxel may be offered as an alternative.
Intravesical chemotherapy is not used when there’s a suspected bladder perforation or after an especially extensive surgical resection, because the drug could leak outside the bladder into surrounding tissue.
Common Medications Used
The two chemotherapy drugs most frequently placed into the bladder are mitomycin C and gemcitabine. Both work by damaging the DNA of rapidly dividing cancer cells on the bladder wall, preventing them from growing or surviving. A newer combination pairs gemcitabine with docetaxel, typically reserved for patients whose cancer has returned after other treatments. Your oncologist or urologist will choose a drug based on your cancer’s risk level and your treatment history.
What the Procedure Feels Like
The treatment itself is done in an outpatient clinic and takes about one to two hours total. You’ll lie on an exam table while a nurse or provider inserts a thin, flexible catheter through your urethra. This may cause brief discomfort or a sensation of pressure, but it’s not typically described as painful. Once the catheter is in place, your bladder is emptied so the medication won’t be diluted by residual urine. The drug is then slowly instilled into the bladder.
After the medication is in, the catheter is either removed or clamped shut, and you hold the solution in your bladder for a specified dwell time, usually one to two hours. During this time, you may be asked to shift positions periodically so the drug coats all surfaces of the bladder lining. If you have difficulty holding the solution, a catheter with a plug can remain in place to keep the medication from leaking out. At the end of the dwell time, you either urinate normally or the solution is drained through the catheter before it’s removed.
Side Effects
Because the drug stays in the bladder rather than circulating through the body, side effects are primarily local. After each treatment, you may notice a burning sensation when you urinate, a frequent or urgent need to go, and light pink or reddish urine. Some patients also pass small pieces of tissue or scab-like material in their urine, which comes from the healing bladder lining. These symptoms typically resolve within a day or two.
Systemic side effects like fatigue, nausea, hair loss, and lowered blood counts are uncommon with intravesical chemotherapy precisely because so little of the drug enters the bloodstream. That said, the bladder lining can become irritated over the course of multiple treatments, and some patients find that side effects build gradually during a six-week induction course.
Precautions After Treatment
For several hours after each session, your urine contains active chemotherapy drug. Most clinics advise sitting down to urinate (to avoid splashing), flushing twice after each use, and washing your hands and genital area thoroughly. Adding a cup of household bleach to the toilet bowl before flushing can help neutralize any residual medication. These precautions are typically recommended for about six hours after treatment.
You’ll also want to drink plenty of fluids in the hours after the drug is drained from your bladder to help flush any remaining traces through your system. Skin that comes into contact with the medication or treated urine should be washed with soap and water right away.
How Effective It Is
Bladder cancer has one of the highest recurrence rates of any cancer, which is precisely why intravesical therapy is so important. A single post-operative dose of chemotherapy reduces early recurrences (within one year) by about 12% and extends the overall recurrence-free period by 38% compared to surgery alone. For patients who undergo the full six-week induction course, recurrence rates drop further, though the exact benefit depends on the individual’s risk category and how well they respond.
Intravesical chemotherapy does not eliminate the need for regular follow-up. Bladder cancer surveillance, which includes periodic cystoscopies (a camera exam of the bladder), continues for years after treatment. The goal of intravesical therapy is to reduce how often cancer returns and to manage recurrences without requiring more aggressive surgery like bladder removal.